Share This Page
Drug Price Trends for HADLIMA PUSHTOUCH
✉ Email this page to a colleague
Average Pharmacy Cost for HADLIMA PUSHTOUCH
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | 78206-0184-01 | 632.24125 | ML | 2026-02-18 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | 78206-0184-01 | 632.24125 | ML | 2026-01-21 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | 78206-0184-01 | 632.24125 | ML | 2025-12-17 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | 78206-0184-01 | 632.28958 | ML | 2025-11-19 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | 78206-0184-01 | 632.24125 | ML | 2025-10-22 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | 78206-0184-01 | 630.54750 | ML | 2025-08-20 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | 78206-0184-01 | 630.54750 | ML | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for HADLIMA PUSHTOUCH
Executive Summary
HADLIMA PUSHTOUCH, a biosimilar candidate for the reference biologic Humira (adalimumab), holds significant market potential as healthcare systems shift towards cost-effective biologic alternatives. This report provides a comprehensive market landscape analysis, examines current pricing strategies, projects future price trajectories, and evaluates competitive dynamics for HADLIMA PUSHTOUCH over the coming five years. It synthesizes regulatory developments, market demand, pricing policies, and reimbursement trends that influence biosimilar adoption, delivering insights essential for stakeholders in pharmaceutical pricing, market entry, and strategic planning.
What Is HADLIMA PUSHTOUCH?
HADLIMA PUSHTOUCH is a biosimilar candidate intended for subcutaneous administration, targeting autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease. Developed by Samsung Bioepis, HADLIMA (also known as SB5) is designed to be highly similar to Humira, with no clinically meaningful differences in safety, purity, or potency.
Clinical & Regulatory Status
- Indications: Rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease.
- Regulatory approvals: Approved or under review in multiple jurisdictions including the EU, US, and Japan as of late 2022.
- Manufacturing: Large-scale biosimilar manufacturing facilities with approval pathways aligned with FDA and EMA guidelines.
Market Landscape: Biosimilars for Humira (Adalimumab)
Current Market Dynamics
| Aspect | Details |
|---|---|
| Reference biologic | Humira (adalimumab); global sales peaked at ~$20.4 billion in 2021 [1]. |
| Number of biosimilar competitors | Over 10 biosimilars approved or in development worldwide [2]. |
| Market penetration factors | Patent expirations (US: Jan 2023; EU: Oct 2018) catalyzed biosimilar entry; physicians’ confidence increasing [3]. |
| Market size (2019–2023) | Expected to grow from $8 billion (2019) to over $20 billion by 2025 across various markets [4]. |
Key Markets & Adoption Trends
| Region | Biosimilar Market Share (2022) | Price Reduction Effect | Reimbursement Policies |
|---|---|---|---|
| North America | ~25% | 15-35% discount from originator | Favorable; formulary inclusions increase biosimilar utilization [5] |
| Europe | ~45% | 30-50% discount | Established pathways; physician acceptance high [6] |
| Asia-Pacific | Emerging; ~10-20% market share | 10-25% discount | Growing adoption, with local manufacturing support [7] |
Price Strategies and Projections for HADLIMA PUSHTOUCH
Historical Pricing Trends
- Humira (Originator): Peak US list price (2021) ~$60,000 annually per patient.
- Biosimilar Pricing: Discounts vary based on market, ranging from 15% to over 50% off originator prices [8].
Current Price Benchmarks (2022–2023)
| Market | Approximate Price (per patient/year) | Discount from Humira (%) | Key Pricing Policies |
|---|---|---|---|
| US | ~$30,000–$45,000 | 25–50% | Competitive bidding; payer negotiations prevalent |
| EU | €15,000–€25,000 | 30–50% | Reimbursement pathways favor biosimilars |
| Japan | ¥2,000,000–¥3,000,000 | 20–40% | Policy incentivizes biosimilar uptake |
Projected Price Trends (2024–2028)
| Year | Expected Price Range (per patient/year) | Key Influencers |
|---|---|---|
| 2024 | $20,000–$35,000 | Early biosimilar market adoption, payer negotiations |
| 2025 | $18,000–$30,000 | Increased competition, price erosion, policy pressures |
| 2026 | $15,000–$25,000 | Mature biosimilar market, policy-driven incentives |
| 2027 | $12,000–$20,000 | Market saturation, innovation in biosimilar manufacturing |
| 2028 | $10,000–$18,000 | Consolidation, preferential formulary positioning |
Note: These estimates assume no major policy disruptions but reflect the typical downward pricing trajectory observed in biosimilar markets.
Competitive and Regulatory Factors Impacting Prices
Biosimilar Market Penetration Drivers
- Patent Expiry and Litigation: Timely patent expirations and legal clearances influence market entry speed.
- Regulatory Pathways: EMA’s abbreviated pathway (2013) and FDA’s biosimilar approval framework (2015) accelerate access.
- Physician and Patient Acceptance: Education and clinical evidence bolster confidence.
- Reimbursement & Policy: Favorable reimbursement policies, prescriber incentives, and formulary inclusions foster uptake.
Policy Influences and Pricing Controls
| Policy Area | Impact | Jurisdiction Examples |
|---|---|---|
| Price caps and negotiation policies | Cap maximal prices for biosimilars | NHS in UK, Germany, Ontario (Canada) |
| Incentives for biosimilar substitution | Preference for biosimilars at pharmacy level | US pharmacy benefit managers, EU tenders |
| Exclusivity and patent law reforms | Accelerate biosimilar entry | US-ACT (Affordable Care Act), EU patent regulations |
Comparative Analysis: HADLIMA PUSHTOUCH Versus Competitors
| Biosimilar Name | Manufacturer | Approval Year | List Price (US) | Market Share (2022) | Discount vs Humira | Notable Features |
|---|---|---|---|---|---|---|
| Amjevita (Amgen) | Amgen | 2016 | ~$30,000 | 12% | 50% | First US-approved Humira biosimilar; multiple indications |
| Cyltezo (Boehringer) | Boehringer Ingelheim | 2017 | ~$31,000 | 10% | 48% | Subcutaneous formulation, U.S. approval |
| Hadlima (Samsung Bioepis) | Samsung Bioepis | 2018 (EU), 2022 (US) | ~$29,000 | 15% | 52% | Strong pipeline, global reach, late market entrant |
Note: Actual pricing varies due to negotiated discounts, rebates, and contractual arrangements.
Market Entry Strategies and Price Positioning for HADLIMA PUSHTOUCH
- Pricing Position: Target 30-50% discount off Humira to maximize market share; align with regional policies.
- Market Differentiation: Emphasize manufacturing quality, extensive indication coverage, and regulatory approvals.
- Partnerships & Payer Engagement: Collaborate with health authorities and insurers to facilitate formulary inclusion and reimbursement.
Forecasting Challenges and Opportunities
| Challenge | Impact | Mitigation Strategies |
|---|---|---|
| Regulatory Delays | Slower market penetration | Strategic regulatory filing across jurisdictions |
| Market Competition | Price erosion, decreased margins | Diversify indications, cost efficiencies |
| Payer Reimbursements & Formularies | Limitations on uptake | Early payer engagement, demonstrable value |
| Patent Litigation | Market entry delays | Intellectual property strategizing |
| Opportunities | Impact | Strategies |
|---|---|---|
| Growing biologics market in emerging markets | Expanding global footprint | Local partnerships, adaptable pricing models |
| Innovation in biosimilar platform technology | Cost reduction, improved quality | Invest in manufacturing and R&D |
| Patient-centric healthcare initiatives | Increased biosimilar utilization | Education campaigns, clinical evidence building |
Conclusion: Price Trajectory and Market Outlook
HADLIMA PUSHTOUCH is positioned to capture a substantial share of the global biosimilar market, riding the expanding wave of biologic substitutions. Initial list prices are expected to range around $28,000–$32,000 in the US, with discounts reaching 50% off Humira. Over five years, market-driven price erosion will likely settle prices around $10,000–$20,000 per patient annually, influenced by regional policies, competitive entry, and payer negotiations. Strategic alignment with evolving reimbursement frameworks and early market engagement will be critical to optimize profitability and market share.
Key Takeaways
- Market Timing: Patent expiries and regulatory pathways position HADLIMA PUSHTOUCH for rapid market entry, particularly in Europe and the US.
- Pricing Strategy: Starting with a 30–50% discount aligns with standard biosimilar positioning, with downward pressure expected over time.
- Market Dynamics: Growing biosimilar adoption is driven by policy incentives, clinician acceptance, and cost savings demands.
- Forecast Trends: Price reductions are projected to stabilize at approximately $10,000–$20,000 within five years, mirroring biosimilar market patterns.
- Competitive Edge: Early engagement, indication expansion, and cost-efficient manufacturing will be decisive for success in a competitive environment.
FAQs
1. What are the main factors influencing the pricing of HADLIMA PUSHTOUCH?
Pricing is primarily affected by regulatory approvals, regional reimbursement policies, manufacturing costs, competitive landscape, and negotiation power with payers.
2. How does HADLIMA PUSHTOUCH compare to other biosimilars of Humira?
It is among the later entrants, with similar pricing and efficacy profiles; its competitive edge hinges on indications coverage, manufacturing scale, and regional approvals.
3. Will prices significantly decline over the next five years?
Yes. Historically, biosimilar prices decrease by approximately 20–50% over five years as market saturation increases and competition intensifies.
4. Which regions offer the fastest growth prospects for HADLIMA PUSHTOUCH?
Emerging markets in Asia-Pacific and established markets in Europe are poised for significant growth due to supportive policies and existing biosimilar infrastructure.
5. How do reimbursement policies impact biosimilar pricing?
Favorable policies, including price caps and incentivized substitution, can constrain pricing but accelerate market penetration, creating a balance between affordability and profitability.
References
[1] IQVIA, "Global Biologic Sales Data," 2022.
[2] Biosimilar Development Pipeline, FDA and EMA listings, 2022.
[3] European Medicines Agency, "Biosimilar Approvals," 2021.
[4] Evaluate Pharma, "Biologics Market Forecast," 2022.
[5] National Health Service (NHS), "Biosimilar Policy Framework," 2021.
[6] EMA, "Market Penetration Reports," 2022.
[7] Asia-Pacific Biologics Market Report, 2022.
[8] MarketScan, "Biosimilar Pricing Trends," 2022.
This report provides a strategic foundation for stakeholders interested in HADLIMA PUSHTOUCH’s market positioning, pricing policies, and revenue potential, enabling data-driven decision-making amidst a dynamic biosimilar landscape.
More… ↓
